The introduction of H2-receptor antagonists in the mid-1970s provided, for the first time, acceptable medical therapy for acid-related diseases. Their short duration of action and single receptor targeting, however, limited satisfactory treatment of patients. Today the control of gastric acid secretion can be effectively achieved by direct inhibition of the H+, K+-ATPase. Inhibition of the proton pump suppresses acid secretion independent of the route of stimulation. Two classes of drugs are able to inhibit the proton pump. First, the substituted benzimidazoles (proton pump inhibitors [PPIs]), which, due to their pKa of about 4, accumulate in the acidic secretory canaliculus of the stimulated parietal cell. Following conversion to a cationic sulfenamide, they react with cysteines on the extracytoplasmatic face of the H+, K+-ATPase subunit. Second, acid pump antagonists (APAs) acting by K+-competitive and reversible binding to the gastric proton pump, which is the final step for activation of acid secretion in the parietal cell.
One possible class ofAPAs are imidazopyridines. BY841 was selected from this class and is chemically a (8-(2-methoxycarbonylamino-6-methyl-phenylmethylamino)-2,3-dimethyl-imidazo [1,2-a]-pyridine). In pharmacological experiments such as pH-metry in the conscious, pentagastrin-stimulated fistula dog, BY841 proved to be superior to both ranitidine and omeprazole by rapidly elevating intragastric pH up to a value of 6. The duration of this pH elevation in the dog was dose-dependent.
As was predicted by the above-mentioned dog model, available clinical phase I data confirm dose-dependent pharmacodynamics of BY841 in man. Using both acid output and continuous 24-hr pH measurements, a pronounced antisecretory effect of BY841 has been found. Actually, a single 50 mg oral dose of BY841 immediately elevated intragastric pH to about 6. Higher doses caused a dosedependent increase in duration of the pH-elevation, without any further increase in maximum pH values. Twice daily administration was more effective than once a day administration of the same daily dose. With both regimens, the duration of the pH-elevating effect of BY841 further increased upon repeated daily administration. This demonstrates lack of tolerance development, the latter being a well-known disadvantage of H -receptor antagonists. In comparison with the standard dose of omeprazole, BY841 administered at a dose of 50 mg or 100 mg twice daily is markedly more effective on Day one of treatment, and both doses are at least as potent as omeprazole following repeated daily admin-
INTRODUCTION
The introduction of H2-receptor antagonists (H2RAs)b about 20 years ago provided, for the first time, acceptable effective medical therapy for acid-related diseases. However, due to their single receptor targeting, the acid-suppressing effect can be overcome by stimulation via other pathways. Further teristics of these inhibitors are the competition for the K+-binding at the proton pump and the reversibility of this binding (i.e., inhibition of the enzyme). The latter can be demonstrated by dilution experiments. Due to these properties, compounds of this type are socalled acid pump antagonists (APAs). The structural differences between the proton pump and the sodium pump allow K+-competition by the APA at the proton pump only, whereas the inhibition of the sodium pump is low and seems to be non-competitive (data not shown). SCH28080 (Schering) was the first APA in preclinical and clinical development followed by the chinoline derivatives BY067 and BY574. The inhibitory potency of antisecretory compounds is expressed in terms of their IC50 values (i.e., the concentration of agent required to cause a 50 percent inhibition).
Thus, as can be seen from Table 1 , BY841 has the lowest IC50 value and is therefore the most potent of the three compounds. The ratio of the ICSO values for the sodium vs. the proton pump as an index for the selectivity was at least one order of magnitude greater for BY841 than for BY067 and BY574. Hence, BY841 has the greatest selectivity for the proton pump (Table 1) .
In both screening models, the pentagastrin-stimulated Ghosh Schild Rat and the histamine stimulated Heidenhain Pouch Dog, BY841 proved to be the most potent compound ( Table 2 , for methods see [1] ).
pH-metry in the conscious and fasted pentagastrin-stimulated fistula dog (for methods, see [2] ) BY841 proved to be superior to both ranitidine [3] and omeprazole by rapidly elevating intragastric pH up to values of about 6 even after a single oral dose of about 10 mg/kg. The duration of this pH elevation in the dog was dose-dependent [3] . In this experimental model, BY841 was also more effective than ranitidine in suppressing carbachol-stimulated acid secretion. Due to its unique pH profile and potency, BY841 was chosen for further clinical development. Its chemical structure is shown in Figure 1 . 
PHASE I CLINICAL TRIALS WITH BY841 Materials and Methods
All study protocols were approved by independent ethics committees, and written informed consent by each volunteer was obtained prior to the start of the study.
In pH-metry studies, intragastric pH was continuously recorded over 24 hours using a DL70 recorder (Sch6nfeld Datentechnik, Karlsruhe, Germany) and Ingold glass electrodes M440 (Ingold, Urdorf, Switzerland). Study 1: Single increasing oral doses, pH-metry Healthy male subjects (n = 18) were admitted to the study and divided into three groups of six subjects each. Their age ranged from 23 to 42 years (median: 27.5) and their body weight, from 65 to 86 kg (median: 73).
Each subject was given two single oral doses of BY841 in increasing order with interposed placebo administration. There was a wash-out period of at least one week between two consecutive treatment days. led to a prolongation of the pH elevation without further increase in maximum pH values ([5] , Figure 2 ). Study 2: Single oral doses produced a dose-dependent inhibition of PSAO. Inhibition was nearly complete at doses of 200 mg or 400 mg. Inhibition of the secreted volume paralleled that of acid output, but to a lesser extent ([6] , Table 3 ). Study 3: Intake of 100 mg both in the morning and in the evening rapidly raised intragastric pH. The effect of the evening dose lasted longer than that of the morning dose. On Day one, the effect of 200 mg was superior to that of 100 mg, however, on Day seven there was nearly no difference between the 100 mg morning and the 200 mg dose. The evening dose of 100 mg produced a marked elevation of pH throughout the night even after the first dose. In contrast, the 200 mg dose administered once daily in the morning showed nearly no effect on nighttime pH. Thus, twice daily administration is more effective than once a day administration of the same daily dose. With both treatment regimens, the effect, particularly during the day, increased upon repeated dosing, the increase being more pronounced with twice daily dosing ([7] , Figures 3 and 4 ). Study 4: In comparison to baseline values, both doses of BY841, 50 mg twice daily and 100 mg twice daily, markedly elevated intragastric pH and prolonged percent of time of pH > 4 even on Day 1. In contrast, only minor effects were observed with 20 mg omeprazole once daily ( Figure 5 ). Repeated daily administration led to an increase in suppression of intragastric acidity with all three treatment regimens. On Day 7, the effect of 50 mg and 100 mg BY841 twice daily was at least comparable to that of 20 mg omeprazole once daily (Table 4, Figure 6 ). Pharmacokinetics Study 2: BY841 was rapidly absorbed. Maximum serum concentrations were attained between 0.5 and 1.5 hr following administration (Figure 7) . Median Cmax-and AUC-values increased with dose and ranged from 0.2 to 1.9 mg/l (Cmax) and from 0.3 to 4.1 mgxhll/ (AUC) for the doses 20 to 400 mg. BY841 was eliminated monophasically from serum. Its serum elimination half-life was short, median values ranging from 1.1. to 1.7 hours. AUC and Cmax of BY841 were higher following a 200 mg than one 100 mg dose, although the increase was less than dose-proportional. T1/2 and tmax seemed to be independent of the dose. The elimination half-life of BY841 was unchanged following repeated doses at either dose level. In duodenal ulcer, the pH threshold for optimal healing is 3 (10) . Similar criteria apply for gastric ulcer where the duration of treatment is important and the model of pH 3 holds good at eight weeks (11) . For gastro-esophageal reflux disease the critical threshold for intragastric pH is 4 at eight weeks (12) . Hence, BY841 at a dose of 50 mg or 100 mg twice daily should be at least as effective in treatment of patients as the standard dose of omeprazole. However, BY841 is markedly more effective in suppressing intragastric acidity during the first days of treatment, a shortening of the healing time and an even more rapid pain relief may be expected.
BY841 was rapidly absorbed. Cmax and AUC increased with increasing dose in the dose range 20 to 400 mg. Its serum elimination, half-life was short and unchanged upon repeated administration. Slightly increased AUC-values upon repeated administration corresponded with an increase in the pharmacodynamic effect.
As to H. pylori eradication, administration of BY841 in combination with one antibiotic should result in high and predictable pH values of about 6 in particular during the period when maximum serum concentrations of the antibiotic are achieved. Profound acid suppression seems to have a synergistic effect on H. pylori eradication (13) . Whether dual therapy with BY841 and one antibiotic therefore improves H. pylori eradication remains to be investigated in clinical trials.
Further advantages are that an acid pump antagonist such as BY841 is acid-stable and hence, does not have to be protected from gastric acid by enteric coating. It acts irrespective of the activation state of the proton pump. The latter also means that a resting parietal cell is inhibited and can not be subsequently stimulated to secrete acid.
In conclusion, BY841 is unique among the acid-suppressing drugs because it combines the advantages of both H2RAs and proton pump inhibitors and should therefore further improve the therapy of acid-related diseases.
